Vaccine Info

Delta gD-2 (∆gD-2) Herpes Vaccine

∆gD-2 Herpes Vaccine Description

The ∆gD-2 herpes vaccine candidate elicits antibodies that facilitate the killing of infected cells, which then rapidly clears the HSV-1 and HSV-2 viruses.

The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cell-mediated killing (ADCK) as the primary mechanism of protection. ADCK is induced to flag infected cells for destruction by natural immune cells.

X-Vax Technology, Inc. is a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we are taking could succeed in defeating herpes. We have created a herpes vaccine candidate that we call ∆gD-2 (delta gD-2) because it is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, we have been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models—with encouraging results.

∆gD-2 Herpes Vaccine Indication

∆gD-2 Herpes Vaccine candidate is indicated to clear the virus as well as prevent latency.  Latency is a non-replicating state which periodically will reactivate resulting in lifelong infection as well as the ongoing risk of shedding the virus to others.

∆gD-2 Herpes Vaccine News

June 16, 2020 - A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.

October 10, 2019 - Murine Model of Maternal Immunization Demonstrates Protective Role for Antibodies That Mediate Antibody-Dependent Cellular Cytotoxicity in Protecting Neonates From Herpes Simplex Virus Type 1 & Type 2.

July 23, 2019: Proceeds from the $56 million Series A financing will be used to advance X-VAX's lead program, a vaccine candidate against herpes, called ∆gD-2 (delta gD-2) for further development and production, including a Phase 1 clinical study. "We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity," added William Jacobs, Ph.D., co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine.

August 4, 2016 - HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates.

Updated
08/24/2020 - 07:04